A young-onset type 2 diabetic Chinese girl with familial renal glycosuria caused by a novel mutation in SLC5A2: A case report

Abstract

The pathogenesis of youth-onset type 2 diabetes is different from that of maturity-onset diabetes of the young (MODY) and from type 1 diabetes, but there are many overlapped clinical manifestations among these three types of diabetes. Delays in differential diagnosis and incorrect treatment will definitely cause worse prognosis. If hyperglycemia cannot be well controlled in diabetic patients, hyperglycosuria and even ketonuria will be present.

Proximal tubules in the kidneys can reabsorb 180 g glucose every day in physiological conditions. If plasma glucose concentrations are in the normal range (< 200 mg/dL), all the filtered glucose will be reabsorbed in the proximal renal tubules. As a result, no urinary glucose is excreted.¹

Familial renal glycosuria (FRG) is a rare genetic disorder of proximal tubular glucose transport, characterized by excessive urinary glucose excretion even if blood glucose level is in normal range. It has been confirmed that mutations in the solute carrier family 5 members 2 (SLC5A2) gene, which encodes sodium-glucose cotransporter 2 (SGLT2), are responsible for this disease.² The SLC5A2 gene is a 7.7 kb gene containing 14 exons and encoding protein SGLT2, with 672 amino acids and an inferred secondary structure consisting of 14 transmembrane-spanning domains and expressed in the S1 and S2 segments of the proximal convoluted tubule, which account for 90% of renal glucose reabsorption.³ FRG may be transmitted in an autosomal dominant pattern, although current studies demonstrated that its inheritance may be codominant with incomplete penetrance. FRG is a benign condition, which does not need any treatment, and the prognosis of patients with this disorder is usually favorable.

There is no report about youth-onset type 2 diabetes associated with FRG. Herein we described the clinical characteristics of a Chinese girl with youth-onset type 2 diabetes coexisting with FRG, in whom a novel mutation (NM_003041.4:c.1129 + 2 T > C) of the SLC5A2 gene might explain FRG occurrence.

The patient presented with polydipsia, polyuria, and weight loss at age 14 years. Endocrinological evaluations showed fasting and postprandial serum insulin and C-peptide in the normal range, with negative islet autoantibodies, thus excluding type 1 diabetes diagnosis and presuming the MODY one.

MODY is a special type of diabetes mellitus, representing a small but very important fraction of diabetic patients (1%–5%),^{4, 5} and 1%–6% of cases in pediatric age.⁶ In this patient, no mutations in 14 genes associated with MODY have been detected, and its diagnosis was also excluded.

The clinical presentation of youth-onset type 2 diabetes resembles that of MODY, but these patients are usually overweight or obese. The diagnosis of youth-onset type 2 diabetes was confirmed in the present patient, and other types of diabetes mellitus were excluded.

The proband underwent insulin and metformin treatment, performed also at high doses, not allowing however to limit glycosuria and ketonuria even when blood glucose levels almost reached the normal range. Then, a possible concurrent FRG diagnosis was supposed.

FRG is a rare renal tubular disorder in which patients present isolated persistent glycosuria without abnormal glucose metabolism and other proximal tubular disorder. Previous studies confirmed that SLC5A2 gene mutations are responsible for FRG. Most of patients with heterozygous mutations have slight glycosuria (<10 g/d) or no glycosuria, whereas other individuals with homozygous or compound heterozygous mutations usually have serious glycosuria (>10 g/d).⁷ Qian Ren research showed that the urine glucose excretion was significantly higher in patients with homozygous mutations than those with compound heterozygous ones.⁸ To date, 115 variants in the SLC5A2 gene were identified. The most frequent ones include missense, frameshift, and splicing mutations.⁹ They appear to affect transport activity through decreasing intrinsic transporter activity, reducing protein insertion into cell membrane, inhibiting protein synthesis, and accelerating protein degradation. FRG is a benign condition, which does not need any specific treatment, because it causes no apparent symptoms or severe outcomes, such as hypoglycemia, polyuria, or dehydration.

In this family, a heterozygous variation was detected in the SLC5A2 gene (NM_003041.4:c.1129 + 2 T > C) in the proband and her father. The novel mutation occurred at the exon-intron boundaries. Theoretically, the mutation can affect the normal cleavage of mRNA. To date, this variation has not been reported in literature or in large-scale population frequency databases. According to the clinical manifestations presented in the proband, we considered the SLC5A2 mutation detected as likely pathogenic, based on the variation classification guidelines of ACMG. SGLT2 plays a key role in sugar binding and translocation in proximal convoluted tubule. Its mutation can lead to SGLT2 impaired function, decreasing the reabsorption of glucose from the filtered urine and reducing blood glucose together with sodium depletion, and being thus responsible for glycosuria and osmotic diuresis. As a result, this youth-onset type 2 diabetic patient also had continuous glycosuria. Theoretically, we hypothesized the hyperglycemia is more easier to be controlled in type 2 diabetes patients coexisting with FRG. However, this phenomenon was not observed in this patient, because her blood glucose levels were not well controlled with a higher dose of insulin combined with metformin. It has been hypothesized that, because lipolysis within the adipose tissues and the free fatty production acids will increase, subsequently an uninhibited transport of fatty acids into hepatic mitochondria and ketone bodies production through ß-oxidation may occur.¹⁰ Actually, SGLT2 inhibition can directly act on pancreatic α-cells to increase secretion of glucagon, leading to the propensity of ketone production. SLC5A2 gene mutations and then SGLT2 dysfunctions might be responsible for glucagon hypersecretion, thus causing continuous glycosuria and ketonuria even when blood glucose is near the normal range.

The proband and her father had different phenotypes even though they had the same mutation. Such variants are referred to as incomplete penetrance, leading to a wide range of diverse phenotypes, from asymptomatic cases to severe disease among related individuals. Both incomplete penetrance and variable expressivity are thought to be caused by many factors, including common variants, variants in regulatory regions, epigenetics, environmental factors, and lifestyle.^{11, 12} The inheritance of FRG is usually confirmed as codominant with incomplete penetrance, because not all patients with similar or identical mutations have the same degree of excessive glucose excretion.¹³ Our finding was consistent with the literature reports.

Additionally, the patient suffered from recurrent UTI. Diabetic women have an increased incidence of recurrent UTI compared with nondiabetic patients, as excessive glucose in the urine can enhance bacterial growth. It may be worse in our diabetic female patient also affected with FRG, because glycosuria and consequent predisposition to growth of commensal microorganisms were more serious.

The etiologies of diabetes mellitus are different, and diabetic patients usually present with many characteristics. Thus, the differential diagnosis is usually difficult, especially when diabetic patients concurrently suffer from other rare diseases, which may interfere with glucose homeostasis as observed in the present patient. Clinicians should enhance their ability to distinguish such complex phenotypes and perform early and careful clinical evaluation in these patients.^{14, 15} Genetic investigations, including next generation sequencing, are extremely useful in identifying specific gene mutations in the patients, or in their family members, as well as to ensure the most appropriate therapy and follow-up.^16-19

Yuqing Qu and Xianling Wang conceived of and designed the work. Limei Hao acquired the data. Yuqing Qu analyzed the data and drafted the manuscript. Xianling Wang critically revised the manuscript for important intellectual content. All authors were responsible for the interpretation of the data and revised and gave final approval of the manuscript. Xianling Wang is the guarantor of the work and, as such, had full access to all the data and takes responsibility for the integrity of the data and the accuracy of the data analysis.

This study did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.